Comorbidity between depression and cardiovascular disease

International Angiology

Volumn 28, Issue 2, 2009, Pages 92-99

  Halaris, A ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Blood platelets; Cardiovascular diseases; Depression; Inflammation; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; ARGININE; BETA THROMBOGLOBULIN; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; ENDORPHIN; NITRIC OXIDE; NORSERTRALINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THROMBOCYTE FACTOR; THROMBOCYTE FACTOR 4; AUTACOID;

ADRENERGIC SYSTEM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DEPRESSION; DISEASE COURSE; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HEART RATE VARIABILITY; HOMEOSTASIS; HUMAN; HYPERCOAGULABILITY; HYPERCORTISOLISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE SYSTEM; INFLAMMATION; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; NEUROENDOCRINE SYSTEM; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PROGNOSIS; PSYCHOPHYSIOLOGY; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; SOCIAL SUPPORT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; UNSPECIFIED SIDE EFFECT; VAGUS TONE; BLOOD; CARDIOVASCULAR DISEASES; METABOLISM; NEUROSECRETION; PSYCHOLOGY; RISK ASSESSMENT; THROMBOCYTE; VASCULAR ENDOTHELIUM;

BLOOD PLATELETS; CARDIOVASCULAR DISEASES; COMORBIDITY; DEPRESSION; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION MEDIATORS; NEUROSECRETORY SYSTEMS; NITRIC OXIDE; RISK ASSESSMENT; RISK FACTORS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 67650502773     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences. Eur Heart J 2004;25:1197-1207 (Pubitemid 38891569)
2. American Heart Association. Heart Disease and Stroke Statistics - 2004 update. Dallas, TX: American Heart Association; 2004.
3. Doris CJ, Ebmeier K, Shajahan P. Depressive illness. Lancet 1999;354:1369-1375
4. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of CVD and implications for therapy. Circulation 1999;99:2192-2217 (Pubitemid 29196806)
5. Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-1442 (Pubitemid 27212192)
6. Fielding R. Depression and acute myocardial infarction: A review and reinterpretation. Soc Sci Med 1991;32:1017-27.
7. Schleifer SJ, Macari-Hinson MM, Coyle DA. The nature and course of depression following myocardial infarction. Arch Intern Med 1989;49:1785-1789 (Pubitemid 19200834)
8. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact of 6-month survival. JAMA 1993;270:1819-1825 (Pubitemid 23301435)
9. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infraction. Circulation 1995;91:999-1005.
10. Lesperance F, Frasure-Smith N, Jueau M, Theroux P. Depression and 1-year prognosis in unstable angina. Arch Intern Med 2000;160:1354-1360 (Pubitemid 30252784)
11. Ahern, DK, Gorkin L., Anderson JL, Tierney C, Hallstrom A, Ewart C et al. Biobehavioral variables and mortality or cardiac arrest in the Cardiac Arrhythmia Pilot Study (CAPS). Am J Cardiol 1990;66:59-62. (Pubitemid 20215719)
12. Bush DE, Ziegelstein RC, Tayback M, Richter D, Stevens S, Zahalsky H, Fauerbach JA. Even minimal symptoms of depression increase mortality risk after acute myocardial infection. Am J Cardiol 2001;88:337-341 (Pubitemid 32823291)
13. Ford DE, Mead LA, Chang PP. Depression is a risk factor for coronary artery disease in men: the precursors study. Arch Intern Med 1998;158:1422-1426 (Pubitemid 28317757)
14. Ariyo AA, Haan M, Tangen CM, Ruteledge JC, Cushman M, Dobs A. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. Circulation 2000;102:1773-1779 (Pubitemid 30799588)
15. Penninx BW, Beekman AT, Honig A, Deeg DJ, Schoevers RA, van Eijk JT. Depression and cardiac mortality: Results from a community-based longitudinal study. Arch Gen Psychiatry 2001;58:221-227 (Pubitemid 32209674)
16. Jiang W, Alexander J, Christopher E, Kuchibhatia M, Gaulden LH, Cuffe MS. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001;161: 1849-1856 (Pubitemid 32762729)
17. Lesperance J, Frasure-Smith N, Talajic M, Bourassa M. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms in myocardial infarction. Circulation 2002;105:1049-1053 (Pubitemid 34212612)
18. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment. Arch Gen Psychiatry 1998;55:580-592 (Pubitemid 28340345)
19. O'Connor CM, Gurbel PA, Serebruany VL. Depression in ischemic heart disease. Am. Heart J 2000;140:63-69
20. Carney RM, Jaffe AS. Treatment of depression following acute myocardial infarction. JAMA 2002;288:750-751 (Pubitemid 34848230)
21. Otte C, Neylan TC, Pipkin SS, Browner WS, Whooley, MA. Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul Study. Am J Psychiatry 2005;162:2139-2145 (Pubitemid 41598269)
22. Colao A., Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M. Persistence of increased cardiovascular risk in patients with Cushing s disease after 5 years of successful cure. J Clin Endocrinol Metab 1999;84:2264-2272 (Pubitemid 30641990)
23. Smitherman TC, Milam M, Woo J. Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: direct evidence for enhanced platelet reactivity in vivo. Am J Cardiol 1981;48:395-402. (Pubitemid 11014380)
24. Levine SP, Lindenfield J, Ellis JB. Increased plasma concentrations of platelet factor-4 in coronary artery disease. Circulation 1981;64:626-632
25. Laghrissi-Thode F, Wagner WR, Pollock BG. Elevated platelet factor 4 and betathromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 1997;42:290-295 (Pubitemid 27325818)
26. Kuijpers PM, Haumulyak K, Strik JJ. Beta-thromboglobulin and platelet factor 4 levels in post-myocardial infarction patients with major depression. Psychiatry Res 2002;109:207-210 (Pubitemid 34258500)
27. Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR, Kasey S et al. Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996;153:1313-1317 (Pubitemid 26334205)
28. Musselman DL, Marzec UM, Manatunga A, Penna S, Reemsnyder A, Knight BT et al. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry 2000;57:875-882 (Pubitemid 30680021)
29. Nemeroff CB, Musselman DL. Are platelets the link between depression and ischemic heart disease? Am Heart J 2000;140(4 Suppl):57-62.
30. Halaris, A. Piletz, JE. Relevance of imidazoline receptors and agmatine to psychiatry. Ann NY Acad Sci 2003;1009:1-19.
31. Piletz JE, Zhu H, Madakasira S, Pazzaglia P, Lindsay Devane C, Goldman N et al. Elevated P-selectin on platelets in depression: response to bupropion. J Psychiat Res 2000;34:397-404. (Pubitemid 32101556)
32. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 2002;53:503-551 (Pubitemid 36014797)
33. Halaris A, Piletz J. Agmatine: Metabolic pathway and spectrum of activity in brain. CNS Drugs 2007;21:885-900. (Pubitemid 47557104)
34. Maes M, Bosmans E, Suy E, Vandervorst C, DeJonckheere C, Raus J. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiat Scand 1991;84:379-386
35. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:11-38.
36. Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 2002;5:375-388 (Pubitemid 35470357)
37. Lee KM, Kim YK. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int Immunopharmacol 2006;6:1298-1304 (Pubitemid 43890961)
38. Koenig, W. Inflammation and coronary heart disease: An overview. Cardiol Rev 2001;9:31-35
39. Mulvihill NT, Foley JB. Inflammation in acute coronary syndromes. Heart 2002;87:201-204
40. Robbins M, Topol EJ. Inflammation in acute coronary syndromes. Cleve Clin J Med 2002;69(Suppl2):SII130-SII142.
41. Maes M, Bosmans E, Meltzer HY, Scharpe S, Suy E. Interleukin-1 beta: A putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 1993;150:1189-93.
42. Maes M, Van der Planken, Van Gastel A, Desnyder R. Blood coagulation and platelet aggression in major depression. J Affect Disord 1996;40:35-40. (Pubitemid 26294848)
43. Kop WJ, Gottdiener JS, Tangen CM, Fried LP, McBurnie MA, Walston J. Inflammation and coagulation factors on persons > 65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am J Cardiol 2002;89:419-424 (Pubitemid 34142517)
44. Musselman, DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001;158:1252-1257 (Pubitemid 32717699)
45. Connor TJ, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 1998; 62: 583-606. (Pubitemid 28045567)
46. Leonard BE. Brain cytokines and the psychopathology of depression. In: Leonard BE, editor. Antidepressants. Basel: Birkhauser Verlag; 2001. p. 109-120
47. Castanon N, Leonard BE, Neveu PJ, Yirmiya R. Effects of antidepressants on cytokine production and actions. Brain Behav Immun 2002;16:569-574 (Pubitemid 35333736)
48. Leonard BE, Myint A. Inflammation and depression: Is there a causal connection with dementia? Neutox Res 2006;10:149-160
49. von Känel R, Hepp U, Kraemer B, Traber R, Keel M, Mica L et al. Evidence for low-grade systemic proinflammatory activity in patients with posttraumatic stress disorder. J Psychiatr Res 2006;41:744-752
50. Empana JP, Sykes DH, Luc G, Juhan-Vague I, Arveiler D., Ferneres J et al. Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2005;111:2299-2305 (Pubitemid 40647064)
51. Anda R, Williamson D, Jones D, Macera C, Eaker E, Glassman A et al. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology 1993;4:285-294
52. Kamphuis MH, Kalmijn S, Tijhuis MA, Geerlings MI, Giampaoli S, Nissinen A et al. Depressive symptoms as risk factor of cardiovascular mortality in older European men: the Finland, Italy and Netherlands Elderly (FINE) study. Eur J Cardiovasc Prev Rehabil 2006;13:199-206. (Pubitemid 44097724)
53. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 1996;94:3123-3129
54. Di Iorio A, Ferrucci L, Sparvieri E, Cherubini A, Volpato S, Corsi A et al. Serum IL-1beta levels in health and disease: a population-based study. 'The InCHIANTI study'. Cytokine 2003;22:198-205.
55. Biasucci LM. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 2004;110:e560-7.
56. Maes M. Introduction to the special section. Int J Neuropsychopharmacol 2002;5:329-331
57. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci 2001;933:222-34. (Pubitemid 32386037)
58. Vollmer-Conna U, Fazou C, Cameron B, Li H, Brennan C, Luck L et al. Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol Med 2004;34:1289-1297 (Pubitemid 39517159)
59. Lett HS, Blumenthal JA, Babyak MA, Sherwood A, Strauman T, Robins C et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 2004;66:305-315
60. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacol 2000;22:370-9. (Pubitemid 30105765)
61. Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 2001;21:199-206. (Pubitemid 32221058)
62. Kubera M, Kenis G, Bosmans E, Kajta M, Basta-Kaim A, Scharpe S et al. Stimulatory effect of antidepressants on the production of IL-6. Int Immunopharmacol 2004;4:185-92. (Pubitemid 38296348)
63. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 2002;5:401-412 (Pubitemid 35470359)
64. Himmerich H, Binder EB, Künzel HE, Schuld A, Lucae S, Uhr M et al. Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol Psychiatry 2006;60:882-888 (Pubitemid 44527894)
65. Mayer B, Holmer SR, Hengstenberg C, Lieb W, Pfeifer M, Schunkert H. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. Int J Cardiol 2005;103: 182-186 (Pubitemid 41096032)
66. Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006;11:680-684 (Pubitemid 43989814)
67. Mendelson SD. The current status of the platelet 5-HT (2A) receptor in depression. J Affect Disord 2000;57:13-24. (Pubitemid 30119953)
68. Hrdina PD, Bakish D, Chudzik J, Ravindran A, Lapierre YD. Serotonergic markers in platelets of patients with major depression: upregulation of 5-HT2 receptors. J Psychiat Neurosci 1995;20:11-19.
69. Neuger J. El Khoury A, Kjellman BF, Wahlund B, Aberg-Wistedt A, Stain-Malgren R. Platelet serotonin functions in untreated major depression. Psychiatry Res 1999;85:189-198 (Pubitemid 29136758)
70. Shimbo, D, Child J, Davidson K, Geer E, Osende JI, Reddy S et al. Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes. Am J Cardiol 2002;89:331-333 (Pubitemid 34113797)
71. Whyte EM, Pollock BG, Wagner WR, Mulsant BH, Ferrell RE, Mazumdar S et al. Influence of serotonin-transporter-linked promoter region polymorphism on platelet activation in geriatric depression. Am J Psychiatry 2001;158:2074-2076
72. Konopka LM, Cooper R, Crayton JW. Serotonin-induced increases in platelet cytosolic calcium concentration in depressed, schizophrenic, and substance abuse patients. Biol Psychiatry 1996;39:708-713 (Pubitemid 26157606)
73. Delisi SM, Konopka LM, O'Connor FL, Crayton JW. Platelet cytosolic calcium responses to serotonin in depressed patients and controls: Relationship to symptomatology and medication. Biol Psychiatry 1998;43:327-334 (Pubitemid 28137624)
74. Delisi SM, Konopka LM, Russell K, O'Connor FL, Cooper R, Crayton JW. Platelet cytosolic calcium hyper-responsivity to serotonin in patients with hypertension and depressive symptoms. Biol Psychiatry 1999;45:1035-1041
75. Palazzolo DL, Quadri SK. Interleukin-1 inhibits serotonin release from the hypothalamus in vitro. Life Sci 1992;51:1797-1802
76. Zhu CB, Blakely RD, Hewlett WA. The proinflammatory cytokines interleukin-1 beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacol 2006;31:2121-2131 (Pubitemid 44413189)
77. Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003;289:3106-3116 (Pubitemid 37432886)
78. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson C, Bigger JT, Pollock BG et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279:287-291
79. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT et al. Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. JAMA 2002;288:701-709
80. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001;104:1894-1898 (Pubitemid 32983230)
81. Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM et al. for the ENRICHD Investigators. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005;62:792-798
82. Serebruany VL, Glassman AH, Malinin AI, Sane DC, Finkel MS, Krishnan R et al. Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. Blood Coagul Fibrinolysis 2003;14:563-567 (Pubitemid 37083172)
83. Serebruany VL, Glassman AH, Malinin AI et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003;108:939-944 (Pubitemid 37048222)
84. Serebruany VL, Suckow RF, Cooper TB et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. Am J Psychiatry 2005; 162: 1165-1170 (Pubitemid 40770700)
85. Serebruany VL, Suckow RF, Cooper TB, O'Connor CM, Malinin AI, Krishnan KR et al. Immunoendocrine aspects of major depression. Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol. Eur Arch Psychiatry Clin Neurosci 1995;245: 172-178
86. Steptoe A, Wardle J, Marmot M. Positive affect and health-related neuroendocrine, cardiovascular, and inflammatory processes. Proc Natl Acad Sci U S A 2005;102:6508-6512 (Pubitemid 40617473)
87. Brydon L, Magid K, Steptoe A: Platelets, coronary heart disease, and stress. Brain Behav Immun 2006;20:113-119 (Pubitemid 43202075)
88. André P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002;106:896-899 (Pubitemid 34925319)
89. Berk M., Wadee AA, Kuschke RH, O'Neill-Kerr A. Acute phase proteins in major depression. J Psychosom Res 1997;43:529-534 (Pubitemid 27487544)
90. Broadley AJ, Korszun A, Jones CJ, Frenneaux MP. Arterial endothelial function is impaired in treated depression. Heart 2002;88:521-523 (Pubitemid 35221970)
91. Danner M, Kasl SV, Abramson JL, Vaccarino V. Association between depression and elevated C-reactive protein. Psychosom Med 2003;65:347-356 (Pubitemid 36628886)
92. Leo R, Di Lorenzo G, Tesauro M, Razzini C, Forleo GB, Chiricolo G et al. Association between enhanced soluble CD40 ligand and proinflammatory and prothromotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J Clin Psychiatry 2006;67:1760-1766 (Pubitemid 44955158)
93. Marques-Deak AH, Neto FL, Dominguez WV, Solis AC, Kurcgant D, Sato F et al. Cytokine profiles in women with different subtypes of major depressive disorder. J Psychiatr Res 2007;41:152-159 (Pubitemid 44708206)
94. Rybakowski JK, Wykretowicz A, Heymann-Szlachcinska A, Wysocki H. Impairment of endothelial function in unipolar and bipolar depression. Biol Psychiatry 2006;60:889-891
95. Suarez EC, Krishnan RR, Lewis JG. The relation of severity of depressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. Psychosom Med 2003;65:362-368 (Pubitemid 36628888)
96. Thomas AJ, Davis S, Morris C, Jackson E, Harrison R, O'Brien JT. Increase in interleukin-1 beta in late-life depression. Am J Psychiatry 2005;162:175-177 (Pubitemid 40095688)
97. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 2003;170:429-433 (Pubitemid 38010515)
98. Basterzi AD, Aydemir C, Kisa C, Aksaray S, Tuzer V, Yazici K, Göka E. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol 2005;20:473-476
99. Tucci M, Quatraro C, Frassanito MA, Silvestris F. Deregulated expression of monocyte chemoattractant protein-1 (MCP-1) in arterial hypertension: role in endothelial inflammation and atheromasia. J Hypertens 2006;24: 1307-1318 (Pubitemid 43948330)
100. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation 2003;108:2054-2059 (Pubitemid 37337577)